Personalised medicine is becoming an increasingly important part of modern healthcare, as treatments are tailored to the unique needs of individual patients rather than relying solely on standardised pharmaceutical products. However, preparing customised medicines remains a complex and labour intensive process for many pharmacies, with manual compounding methods often creating challenges around consistency, efficiency, and quality control. Advances in automation, software, and pharmaceutical manufacturing are now transforming this field, enabling healthcare providers to produce personalised therapies with greater precision and reliability. Finnish health technology company CurifyLabs is at the forefront of this shift, and the company has secured new funding to accelerate international expansion and further develop its automated compounding platform.
CurifyLabs has raised €12 million in a Series A funding round co led by Sandwater and HealthCap, with participation from Tesi, Lifeline Ventures, along with customers and employees based in the United States.
The investment will support the company’s continued expansion in the US while accelerating product development and strengthening its pharmaceutical manufacturing capabilities.
Modernising Pharmaceutical Compounding
Founded in 2021, CurifyLabs develops technology designed to automate the preparation of personalised medicines within pharmacies.
Its Compounding System Solution combines proprietary software, pharmaceutical excipient bases manufactured according to Good Manufacturing Practice standards, and advanced three dimensional printing technology.
Together, these technologies enable pharmacies to produce customised medications more efficiently than conventional manual compounding methods.
The company believes automation can significantly improve the quality, precision, and reproducibility of personalised pharmaceutical manufacturing.
Combining Automation With Quality Control
CurifyLabs has designed its platform to simplify complex pharmacy workflows while maintaining high quality standards.
Integrated quality control capabilities help pharmacies verify production consistency throughout the compounding process.
By reducing dependence on manual preparation, the system aims to minimise variability while improving operational efficiency.
The combination of software driven workflows and automated manufacturing also allows pharmacists to spend more time focusing on patient care rather than repetitive preparation tasks.
The company views digitalisation as an important step toward modernising personalised medicine production.
Growing Adoption Across International Markets
CurifyLabs says its technology is already being used by pharmacies operating across Europe and in twenty one states throughout the United States.
Growing adoption reflects increasing demand for personalised medicines together with more efficient pharmacy production systems.
As the company’s customer base expands, CurifyLabs plans to strengthen its supply chain to support larger numbers of pharmacy partners while maintaining reliable product availability.
The company believes scalable manufacturing infrastructure will play an essential role in supporting future international growth.
Supporting the Future of Personalised Healthcare
Demand for personalised therapies continues increasing as healthcare providers seek treatments tailored to individual patient needs.
Automated pharmaceutical compounding offers the potential to improve both clinical outcomes and operational efficiency by enabling precise preparation of customised medicines.
CurifyLabs aims to support this transformation by providing pharmacies with integrated digital manufacturing tools capable of delivering consistent and high quality pharmaceutical products.
The company’s technology is intended to help healthcare professionals meet growing demand while maintaining rigorous production standards.
Accelerating Expansion and Product Innovation
The newly secured funding will be used to expand CurifyLabs’ operations across the United States while strengthening customer support and supply chain capabilities.
Investment will also accelerate development of the company’s technology platform, including continued advancement of its latest PharmaPrinter Aurum system.
As healthcare increasingly embraces personalised treatment approaches, demand for reliable automated pharmaceutical manufacturing continues to grow. By combining software, advanced materials, three dimensional printing, and integrated quality assurance within a unified platform, CurifyLabs aims to modernise pharmacy compounding while enabling broader access to safe, efficient, and precisely manufactured personalised medicines across global healthcare markets.